Biotech Connection Singapore

Belkins
Biotech Connection Singapore is part of an international network of non-profit organizations that aims to promote the transfer of ideas from theory to real world applications by providing a platform for fostering interaction between academia, industry and businesses.

Related News

CIPLA AND STEMPEUTICS JOIN FORCES FOR THE LAUNCH OF STEMPEUCEL® IN INDIA

Cipla | August 24, 2020

news image

Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) referred to as "Cipla" today announced that its partner Stempeutics Research Pvt. Ltd has received regulatory approval by the Drug Controller General of India (DCGI) for the launch of Stempeucel® in India. The product is indicated for the treatment of CLI due to Buerger's Disease and Atherosclerotic Peripheral Arterial Disease. It is the first allogeneic cell therapy product to be approved for commercial use in India and the first ste...

Read More

OXITEC UNVEILS FIRST FIELD TRIAL RESULTS FOR CROP-PROTECTING GM MOTHS

Labiotech.eu | January 28, 2020

news image

A study led by Oxitec has shown for the first time that diamondback moths genetically engineered to produce only male offspring can survive in the wild, a solution that shows promise for cutting populations of the crop pest. Caterpillars of the diamondback moth Plutella xylostella are one of the most destructive pests for growers of cabbages, broccoli and cauliflowers. Rising resistance to insecticides is making it progressively more difficult for farmers to deal with the insects effectively....

Read More

MEDTECH

ROCHE SIGNS AN AGREEMENT WITH SYSMEX TO BRING HAEMATOLOGY TESTING INNOVATIONS GLOBALLY

Roche | January 25, 2021

news image

Roche declares that, on 14 December, 2020, it marked a Global Business Partnership Agreement* (GBP) with Sysmex. Under this new system, the gatherings restored their obligation to the long standing Distribution, Sales and Service (DSS) arrangement, permitting Roche to keep on disseminating Sysmex hematology items, including instruments and reagents. This GBP sees the presentation of an IT Solutions Collaboration Agreement. In the recently characterized joint effort, the two organizations have co...

Read More

NOVARTIS ACQUIRES VEDERE BIO, A NOVEL OPTOGENETICS AAV GENE THERAPY COMPANY

Vedere Bio | October 29, 2020

news image

Vedere Bio, Inc. (Vedere Bio), a stealth-stage company focused on advancing photoreceptor-protein-based optogenetic therapies that are delivered to the retina intravitreally to restore functional vision, announced today that it has been acquired by Novartis. Shareholders in Vedere Bio received $150 million upfront and will be eligible for up to $130 million in milestone payments, for a total of $280 million. Based on technology from the laboratories of Drs. Ehud Isacoff and John G. Flannery of U...

Read More

Cipla | August 24, 2020

news image

CIPLA AND STEMPEUTICS JOIN FORCES FOR THE LAUNCH OF STEMPEUCEL® IN INDIA

Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) referred to as "Cipla" today announced that its partner Stempeutics Research Pvt. Ltd has received regulatory approval by the Drug Controller General of India (DCGI) for the launch of Stempeucel® in India. The product is indicated for the treatment of CLI due to Buerger's Disease and Atherosclerotic Peripheral Arterial Disease. It is the first allogeneic cell therapy product to be approved for commercial use in India and the first ste...

Read More

Labiotech.eu | January 28, 2020

news image

OXITEC UNVEILS FIRST FIELD TRIAL RESULTS FOR CROP-PROTECTING GM MOTHS

A study led by Oxitec has shown for the first time that diamondback moths genetically engineered to produce only male offspring can survive in the wild, a solution that shows promise for cutting populations of the crop pest. Caterpillars of the diamondback moth Plutella xylostella are one of the most destructive pests for growers of cabbages, broccoli and cauliflowers. Rising resistance to insecticides is making it progressively more difficult for farmers to deal with the insects effectively....

Read More

MEDTECH

Roche | January 25, 2021

news image

ROCHE SIGNS AN AGREEMENT WITH SYSMEX TO BRING HAEMATOLOGY TESTING INNOVATIONS GLOBALLY

Roche declares that, on 14 December, 2020, it marked a Global Business Partnership Agreement* (GBP) with Sysmex. Under this new system, the gatherings restored their obligation to the long standing Distribution, Sales and Service (DSS) arrangement, permitting Roche to keep on disseminating Sysmex hematology items, including instruments and reagents. This GBP sees the presentation of an IT Solutions Collaboration Agreement. In the recently characterized joint effort, the two organizations have co...

Read More

Vedere Bio | October 29, 2020

news image

NOVARTIS ACQUIRES VEDERE BIO, A NOVEL OPTOGENETICS AAV GENE THERAPY COMPANY

Vedere Bio, Inc. (Vedere Bio), a stealth-stage company focused on advancing photoreceptor-protein-based optogenetic therapies that are delivered to the retina intravitreally to restore functional vision, announced today that it has been acquired by Novartis. Shareholders in Vedere Bio received $150 million upfront and will be eligible for up to $130 million in milestone payments, for a total of $280 million. Based on technology from the laboratories of Drs. Ehud Isacoff and John G. Flannery of U...

Read More